Home › Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
 

Keywords :   


Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials

2014-04-30 07:12:40| drugdiscoveryonline News Articles

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced today that GBR 900, a novel monoclonal antibody is entering human trials

Tags: human treatment pain entering

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »